Wedbush Analysts Boost Earnings Estimates for BDTX

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Stock analysts at Wedbush boosted their Q1 2025 EPS estimates for Black Diamond Therapeutics in a research note issued on Wednesday, March 19th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of $0.92 for the quarter, up from their previous forecast of ($0.28). Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. Wedbush also issued estimates for Black Diamond Therapeutics’ FY2025 earnings at $0.07 EPS.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03.

BDTX has been the subject of several other research reports. Stifel Nicolaus cut their price target on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating for the company in a report on Friday, March 7th. HC Wainwright raised their target price on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, March 18th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Black Diamond Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $14.60.

Black Diamond Therapeutics Trading Up 0.6 %

Shares of BDTX stock opened at $1.69 on Monday. The stock has a market capitalization of $95.76 million, a price-to-earnings ratio of -1.27 and a beta of 2.52. Black Diamond Therapeutics has a 12-month low of $1.59 and a 12-month high of $7.66. The stock’s 50-day moving average price is $2.14 and its 200-day moving average price is $2.80.

Institutional Investors Weigh In On Black Diamond Therapeutics

Several institutional investors have recently made changes to their positions in the company. Vestal Point Capital LP grew its holdings in Black Diamond Therapeutics by 11.4% during the 4th quarter. Vestal Point Capital LP now owns 5,600,000 shares of the company’s stock valued at $11,984,000 after purchasing an additional 571,500 shares during the last quarter. Tang Capital Management LLC grew its stake in shares of Black Diamond Therapeutics by 51.1% during the fourth quarter. Tang Capital Management LLC now owns 2,070,209 shares of the company’s stock valued at $4,430,000 after buying an additional 700,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Black Diamond Therapeutics by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 959,316 shares of the company’s stock worth $2,053,000 after buying an additional 14,439 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Black Diamond Therapeutics by 256.2% in the fourth quarter. Renaissance Technologies LLC now owns 904,000 shares of the company’s stock worth $1,935,000 after buying an additional 650,200 shares during the period. Finally, State Street Corp lifted its stake in shares of Black Diamond Therapeutics by 17.2% during the 3rd quarter. State Street Corp now owns 809,196 shares of the company’s stock worth $3,520,000 after acquiring an additional 118,764 shares during the last quarter. Institutional investors own 95.47% of the company’s stock.

Insider Buying and Selling at Black Diamond Therapeutics

In other Black Diamond Therapeutics news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of Black Diamond Therapeutics stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the completion of the transaction, the insider now directly owns 2,733,547 shares of the company’s stock, valued at $5,658,442.29. The trade was a 67.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 8.87% of the company’s stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.